MRVI Stock Forecast: Maravai Lifesciences Holdings, Inc. Price Predictions for 2026-2027
The 9 Wall Street analysts covering Maravai Lifesciences Holdings, Inc. hold a median 12-month price target of $9.5 — +36.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 94 of 100 as at 21 Nov 2026 — among the strongest tenth. Here, the model and the Street point the same way.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Maravai Lifesciences Holdings, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Revisions (94): Analysts have, on balance, been raising their forecasts.
Volatility (32): The share price moves around a lot.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
MRVI stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on MRVI, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +36.1% from it.
Of the 20 most recent actions, 3 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 12 Nov 2026 | Keybanc | Upgrade | Overweight | $11 |
| 9 Sept 2026 | UBS | Maintains | Neutral | $2.50 → $8.00 |
| 7 Aug 2026 | Wells Fargo | Maintains | Overweight | $5.50 → $6.50 |
| 8 May 2026 | Wells Fargo | Maintains | Overweight | $4.50 → $5.50 |
| 15 Dec 2025 | Wells Fargo | Maintains | Overweight | — |
| 12 Aug 2025 | Craig-Hallum | Maintains | Buy | — |
| 12 Aug 2025 | RBC Capital | Maintains | Outperform | — |
| 13 May 2025 | Baird | Maintains | Neutral | — |
| 13 May 2025 | Craig-Hallum | Maintains | Buy | — |
| 25 Mar 2025 | Morgan Stanley | Maintains | Equal-Weight | — |
| 21 Mar 2025 | UBS | Maintains | Neutral | — |
| 3 Mar 2025 | B of A Securities | Maintains | Buy | — |
| 26 Feb 2025 | Baird | Downgrade | Neutral | — |
| 5 Dec 2024 | Goldman Sachs | Downgrade | Sell | — |
| 14 Nov 2024 | Wolfe Research | Initiates | Peer Perform | — |
| 8 Nov 2024 | Baird | Maintains | Outperform | — |
| 8 Nov 2024 | RBC Capital | Maintains | Outperform | — |
| 8 Nov 2024 | William Blair | Downgrade | Market Perform | — |
| 8 Oct 2024 | Goldman Sachs | Maintains | Neutral | — |
| 27 Aug 2024 | Wells Fargo | Initiates | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for MRVI.
This page is one stock. Monday covers all of them.
MRVI appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
MRVI vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Maravai Lifesciences Holdings, Inc. returned +104.1% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
MRVI analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 8.6×
- Price / book
- 5.3×
- EV / EBITDA
- —
Cheaper than 13% of US stocks
Cheaper than 17% of US stocks
- Revenue growth (YoY)
- 10.1%
- Earnings growth (YoY)
- —
- Gross margin
- 40.1%
- Operating margin
- −24.2%
- Net margin
- —
Higher than 54% of US stocks
Higher than 49% of US stocks
Higher than 22% of US stocks
- Return on equity
- −29.8%
- Return on assets
- −4.4%
- Dividend yield
- —
Higher than 28% of US stocks
Higher than 33% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Maravai Lifesciences Holdings, Inc. has a market value of $1.9B and an enterprise value of $1.4B.
Revenue in the twelve months to 30 June 2026: $208.8M. The latest quarter grew 8.5% year on year.
Net income over the same four quarters: −$136.1M, a −65.2% net margin.
Diluted earnings per share, trailing twelve months: −$0.52.
Free cash flow in the twelve months to 30 June 2026: −$35.8M.
Maravai Lifesciences Holdings, Inc. employs 410 people — $509K of revenue per employee.
Data provided by Twelve Data
MRVI and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at MRVI’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Maravai Lifesciences Holdings, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about MRVI
What is the MRVI stock price forecast for 2026-2027?
The 9 Wall Street analysts covering Maravai Lifesciences Holdings, Inc. have a median 12-month price target of $9.5, with estimates ranging from $8 to $12. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is MRVI stock a buy right now?
Of the 9 analysts covering Maravai Lifesciences Holdings, Inc., 6 rate it a Buy, 3 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Maravai Lifesciences Holdings, Inc. 94 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank MRVI?
As at 21 Nov 2026, Maravai Lifesciences Holdings, Inc. ranks 94 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Revisions (94 of 100).
Will MRVI stock go up?
No one can know that. What the data says: the median 12-month target from 9 analysts implies +36.1% from the last close, and Ticker Nerd's factor model ranks Maravai Lifesciences Holdings, Inc. 94 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the MRVI stock forecast for 2030?
No analyst covering Maravai Lifesciences Holdings, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MRVI are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $8 to $12 over the next 12 months.
How has MRVI stock performed over the past year?
Maravai Lifesciences Holdings, Inc. returned +104.1% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Maravai Lifesciences Holdings, Inc. do?
Maravai LifeSciences Holdings, Inc. Class A Common Stock represents ownership in Maravai LifeSciences Holdings, Inc., a life sciences company focused on products and services that support drug development, vaccine creation, cell and gene therapy research, and diagnostics. The company serves biopharmaceutical, biotechnology, and research customers through specialized offerings in nucleic acid production and biologics safety testing.
About Maravai Lifesciences Holdings, Inc.
Maravai LifeSciences Holdings, Inc. Class A Common Stock represents ownership in Maravai LifeSciences Holdings, Inc., a life sciences company focused on products and services that support drug development, vaccine creation, cell and gene therapy research, and diagnostics. The company serves biopharmaceutical, biotechnology, and research customers through specialized offerings in nucleic acid production and biologics safety testing. Its product portfolio includes reagents, enzymes, nucleic acid tools, and analytical services used across molecular biology, genomics, and bioprocessing workflows. Maravai LifeSciences plays a role in the broader healthcare and life sciences market by supplying critical inputs that help enable laboratory research, therapeutic development, and quality testing across the drug development process. The company is headquartered in San Diego, California, and its business is organized around current operating segments that address research and production needs in advanced biologics and diagnostics.
CEO Mr. Bernd Brust · 410 employees · United States · https://www.maravai.com